Clinical Trials Directory

Trials / Completed

CompletedNCT02929849

Satiety and Glucose Indices in Adults

Influence of Herb With Alpha-glucosidase Properties (Salacia Chinensis) on Appetite, Glucose and Hormonal Factors: A Double Blind Randomized Placebo Controlled-crossover Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
51 (actual)
Sponsor
Rutgers University · Academic / Other
Sex
All
Age
20 Years – 59 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine whether an herb with known alpha-glucosidase inhibitor properties (Salacia Chinensis, SC), affects postprandial appetite ratings and glucose indices in overweight/obese individuals.

Detailed description

Subjects are randomly assigned (double blinded) to 300 mg SC, 500 mg SC or placebo using a cross-over design on three different days (1 month wash out). Subjects consuming a capsule containing placebo or treatment(s) are examined before and after a fixed breakfast meal (50% carbohydrate; 30% fat; 20% protein). Subjective appetite sensations are rated using visual analog scales (VAS) for hunger, satiety, fullness, and prospective food intake. In addition, the desire for specific tastes is analyzed and measurements are taken twice before breakfast (fasting baseline). After baseline screening and blood draw, postprandial appetite and taste perception ratings and blood will be obtained at multiple time points during the 3 hour postprandial period (30, 60, 90, 120,180 min). Blood will be analyzed for glucose/insulin, gut peptides, and other markers in response to the meal.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENT300 mg SCSalacia (T1) capsule given with breakfast (mixed meal tolerance test)
DIETARY_SUPPLEMENT500 mg SCSalacia (T2) capsule given with breakfast (mixed meal tolerance test)
DIETARY_SUPPLEMENTPlaceboPlacebo capsule given with breakfast (mixed meal tolerance test)

Timeline

Start date
2015-08-01
Primary completion
2016-06-01
Completion
2021-01-30
First posted
2016-10-11
Last updated
2022-02-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02929849. Inclusion in this directory is not an endorsement.